Acurx Pharmaceuticals, Inc.
ACXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001736243
No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Acurx Pharmaceuticals, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- −3 vs. Q1 2026
- Shares held
- 119.7K
- −62.2K (−34.2%) vs. Q1 2026
- Total value
- $185.5K
- −$488.8K (−72.5%) vs. Q1 2026
- New holders
- 1
- 3 more added
- Sold out
- 4
- 4 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ACXP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 18 | $185.5K |
| Q1 2026 | 21 | $674.2K |
| Q4 2025 | 18 | $345.2K |
| Q3 2025 | 16 | $246.8K |
| Q2 2025 | 32 | $1.33M |
| Q1 2025 | 24 | $1.36M |
| Q4 2024 | 26 | $1.15M |
| Q3 2024 | 22 | $2.41M |
| Q2 2024 | 25 | $2.71M |
| Q1 2024 | 26 | $3.18M |
| Q4 2023 | 23 | $4.24M |
| Q3 2023 | 18 | $1.32M |
| Q2 2023 | 13 | $3.94M |
| Q1 2023 | 12 | $1.86M |
| Q4 2022 | 14 | $5.27M |
| Q3 2022 | 14 | $4.66M |
| Q2 2022 | 12 | $1.43M |
| Q1 2022 | 9 | $1.15M |
| Q4 2021 | 11 | $455.3K |
| Q3 2021 | 8 | $332.0K |
| Q2 2021 | 3 | $163.0K |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Acurx Pharmaceuticals, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 31,099 | $48.2K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 26,411 | $40.9K | 0.00% | +1,592+6.4% | Added |
| Vanguard Fiduciary Trust Co | 16,205 | $25.1K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 15,727 | $24.4K | 0.00% | −38,915−71.2% | Reduced |
| Prospect Financial Services LLC | 13,785 | $21.4K | 0.01% | 00.0% | Unchanged |
| Morgan Stanley | 7,500 | $11.6K | 0.00% | +1,000+15.4% | Added |
| Tower Research Capital LLC (TRC) | 2,744 | $4.25K | 0.00% | +1,713+166.1% | Added |
| Wells Fargo & Company | 2,300 | $3.56K | 0.00% | 00.0% | Unchanged |
| Westside Investment Management, Inc. | 1,650 | $2.56K | 0.00% | 00.0% | Unchanged |
| NBC Securities, Inc. | 1,500 | $2.33K | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 281 | $436 | 0.00% | −99−26.1% | Reduced |
| Cornerstone Planning Group LLC | 167 | $245 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 100 | $155 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 95 | $147 | 0.00% | −150−61.2% | Reduced |
| BlackRock, Inc. | 60 | $93 | 0.00% | 00.0% | Unchanged |
| Caitong International Asset Management Co., Ltd | 23 | $36 | 0.00% | +23 | New |
| SBI Securities Co., Ltd. | 6 | $9 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 3 | $5 | 0.00% | −6,309−100.0% | Reduced |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| McGuire Capital Advisors Inc | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −59−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −1−100.0% | Sold out |